Concepedia

Jessica Read

JR

Statistics

Publications

11

Citations

2.2K

H-Index

11

Active since

2009

Affiliations

AstraZeneca (United Kingdom)(Current)

Genomics Institute of the Novartis Research Foundation

Western Hospital

AstraZeneca (Brazil)

AstraZeneca (United States)

Jessica Read is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

2009–2023

11

Publications

11

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology · 2011 · 1.5K citations · Full text

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

Richard H. De Boer, Óscar Arrieta, James Chih‐Hsin Yang et al. · Journal of Clinical Oncology · 2011 · 289 citations

Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)

R. de Boer, Óscar Arrieta, Maya Gottfried et al. · Journal of Clinical Oncology · 2009 · 88 citations

, , +13

Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine

Susanne Johansson, Jessica Read, Stuart Oliver et al. · Clinical Pharmacokinetics · 2014 · 61 citations

, , +3

Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA).

Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology · 2010 · 61 citations

, , +16

1–5 of 11